Past and future burden of inflammatory bowel diseases based on modeling of population-based data by Coward, Stephanie et al.
Gastroenterology 2019;156:1345–1353Past and Future Burden of Inflammatory Bowel Diseases Based




ATStephanie Coward,1,2 Fiona Clement,2 Eric I. Benchimol,1,3,4,5 Charles N. Bernstein,1,6
J. Antonio Avina-Zubieta,7 Alain Bitton,1,8 Mathew W. Carroll,1,9 Glen Hazlewood,2
Kevan Jacobson,1,10 Susan Jelinski,9,11 Rob Deardon,2 Jennifer L. Jones,1,12
M. Ellen Kuenzig,1,3,4,5 Desmond Leddin,1,13 Kerry A. McBrien,2 Sanjay K. Murthy,1,4,5,14
Geoffrey C. Nguyen,1,5,15,16 Anthony R. Otley,1,12 Remo Panaccione,2 Ali Rezaie,17
Greg Rosenfeld,1,7 Juan Nicolás Peña-Sánchez,1,18 Harminder Singh,1,6 Laura E. Targownik,1,6
and Gilaad G. Kaplan1,2
1Canadian Gastro-Intestinal Epidemiology Consortium, Canada; 2University of Calgary, Calgary, Alberta, Canada; 3Children’s
Hospital of Eastern Ontario IBD Centre and CHEO Research Institute, Children’s Hospital of Eastern Ontario, Ottawa, Ontario,
Canada; 4University of Ottawa, Ottawa, Ontario, Canada; 5ICES, Toronto, Ontario, Canada; 6University of Manitoba, Winnipeg,
Manitoba, Canada; 7Arthritis Research Canada, University of British Columbia, Vancouver, British Columbia, Canada; 8McGill
University, Montreal, Quebec, Canada; 9University of Alberta, Edmonton, Alberta, Canada; 10British Columbia Children’s
Hospital, BC Children’s Hospital Research Institute, University of British Columbia, Vancouver, British Columbia, Canada;
11Alberta Health Services, Edmonton, Alberta, Canada; 12Dalhousie University, Halifax, Nova Scotia, Canada; 13University of
Limerick, Limerick, Ireland; 14The Ottawa Hospital Research Institute and IBD Centre, Ottawa, Ontario, Canada; 15Mount Sinai
Hospital, Toronto, Ontario, Canada; 16University of Toronto, Toronto, Ontario, Canada; 17Cedar Sinai Medical Center, Los
Angeles, California; and 18University of Saskatchewan, Saskatoon, Saskatchewan, CanadaAbbreviations used in this paper: AB, Alberta; AR, autoregressive; ARIMA,
autoregressive integrated moving average; BC, British Columbia; CD,
Crohn disease; CI, confidence interval; IBD, inflammatory bowel disease;
MA, moving average; MB, Manitoba; NS, Nova Scotia; ON, Ontario; PI,
prediction interval; QC, Quebec; SK, Saskatchewan; UC, ulcerative colitis.BACKGROUND & AIMS: Inflammatory bowel diseases
(IBDs) exist worldwide, with high prevalence in North
America. IBD is complex and costly, and its increasing prev-
alence places a greater stress on health care systems. We
aimed to determine the past current, and future prevalences
of IBD in Canada. METHODS: We performed a retrospective
cohort study using population-based health administrative
data from Alberta (2002–2015), British Columbia (1997–
2014), Manitoba (1990–2013), Nova Scotia (1996–2009),
Ontario (1999–2014), Quebec (2001–2008), and Saskatch-
ewan (1998–2016). Autoregressive integrated moving average
regression was applied, and prevalence, with 95% prediction
intervals (PIs), was forecasted to 2030. Average annual per-
centage change, with 95% confidence intervals, was assessed
with log binomial regression. RESULTS: In 2018, the preva-
lence of IBD in Canada was estimated at 725 per 100,000
(95% PI 716–735) and annual average percent change was
estimated at 2.86% (95% confidence interval 2.80%–2.92%).
The prevalence in 2030 was forecasted to be 981 per 100,000
(95% PI 963–999): 159 per 100,000 (95% PI 133–185) in
children, 1118 per 100,000 (95% PI 1069–1168) in adults,
and 1370 per 100,000 (95% PI 1312–1429) in the elderly. In
2018, 267,983 Canadians (95% PI 264,579–271,387) were
estimated to be living with IBD, which was forecasted to in-
crease to 402,853 (95% PI 395,466–410,240) by 2030.
CONCLUSION: Forecasting prevalence will allow health policy
makers to develop policy that is necessary to address the
challenges faced by health systems in providing high-quality
and cost-effective care.Most current article
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Forecast Modeling.he prevalence of inflammatory bowel disease (IBD),Tcomprised of Crohn disease (CD) and ulcerative
colitis (UC), has been increasing globally, with one of
the highest prevalence rates found in Canada.1–4 The inci-
dence of IBD in the latter half of the 20th century increased
significantly in the Western world, which has caused the
prevalence to exceed 0.5% in North America.2
The steadily rising prevalence of IBD can be attributed to
the disease being diagnosed predominantly in young
individuals, being chronic and incurable, and having low
mortality.5 With incidence outpacing death, patients with
newly diagnosed IBD are continually added to the pool of
prevalent patients, leading to the compounding prevalence
of IBD over time.6
IBD is a complex and costly disease owing to an
unpredictable relapsing and remitting course, complica-
tions, hospitalizations, surgeries, and use of expensive
therapies. Thus, the steady increase in the prevalence of IBD
will lead to a substantial increase in the burden borne by
health care systems and society.6
WHAT YOU NEED TO KNOW
BACKGROUND AND CONTEXT
The prevalence of Inflammatory Bowel Disease (IBD) in
Canada is among the highest in the world and is
steadily increasing. However, it is unclear how much the
prevalence will increase in the future.
NEW FINDINGS
In forecasting models, the prevalence of IBD, Crohn’s
disease, and ulcerative colitis are significantly increasing
– with some of the highest rates of increase seen within
the pediatric and the elderly populations.
LIMITATIONS
This comprehensive analysis encompassing of 95% of
the Canadian population lacks the ability to adjust for
possible risk factors (eg, smoking) that affect the risk of
developing IBD.
IMPACT
We are at a time where defining the future prevalence of
disease – to 2030 – is of paramount importance as it
will allow us to prepare for the impending burden.
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ATThe present study aimed to forecast the future
prevalence of IBD in Canada. The Canadian population is
ideal for this study because Canada has a very high preva-
lence of IBD and places a large burden on the single-payer
health care system, making it even more important to
forecast future changes. Estimating the total number of
people diagnosed with IBD will allow health care providers
to proactively implement clinical practices and policy in-
terventions to address the impact of the increasing preva-
lence of IBD.
Methods
Study Population and Data Sources
The Canadian Gastrointestinal Epidemiology Consortium
(CanGIEC) is a national collaboration of provincial IBD
surveillance cohorts derived from administrative health care
databases (Appendix 1). CanGIEC provided retrospective
population-based provincial prevalence data of all individuals
who qualify for health care, of any age, for Alberta (AB; 2002–
2015), British Columbia (BC; 1997–2014), Manitoba (MB;
1990–2013), Nova Scotia (NS; 1996–2009), Ontario (ON; 1999–
2014), Quebec (QC; 2001–2008), and Saskatchewan (SK; 1998–
2016). These provinces account for approximately 95% of the
Canadian population.7
Provincial Estimates
The prevalence of IBD, CD, and UC were calculated for each
province based on years of available data from the provincial
administrative health care databases listed earlier using pop-
ulation values from Statistics Canada (eg, AB historical anal-
ysis was from 2002 to 2015 and forecasted from 2016 to
2030).7 Prevalence rates for each year were standardized for
age and sex based on the Canadian population for the asso-
ciated year.7National Estimates
Canadian population models were calculated by combining
the prevalence for the 7 provinces together from 2002 to
2008—these were the only overlapping years when data were
available from all provinces. Secondary analyses included sex
stratification (male and female) and age stratification into
pediatric (AB, BC, MB, ON, QC, and SK: 0–17 years; NS: 0–19
years), adult (AB, BC, MB, ON, QC, and SK: 18–59 years; NS: 20–
59 years), and elderly (all provinces: 60 years) groups.
Statistical Analysis
The primary forecasting analysis was completed using
autoregressive integrated moving average (ARIMA) models.8–10
An ARIMA model is a time series model in which the value
being assessed is related back to historical values from periods
before the current one; this is a method that has been used in
econometric and prevalence forecasting.8–11 This model was
chosen because of its ability to analyze data at a specific period
and relate those back to data contained in prior periods while
accounting for innate dependence in yearly prevalence data. An
ARIMA model is used for the analysis of equidistant, and
discrete samples of data in a time series model, which is
necessary with the analysis of prevalence data.9,10 The ARIMA
is composed of 3 components (1) autoregressive (AR), model
(2) integrated, term and (3) moving average (MA) model.9–11
The AR model relates the value in a period to historical ones;
the integrated term deals with the assumption of stationarity
(that the probability distribution, mean and variance, remains
constant over time); and the MA model relates the value back to
historical residuals.9–11
First, the AR term, which integrates the prior values into the
current one, can be evaluated using the partial autocorrelation
function, delineating the possible lag periods that are to be
included in the AR model. There can be more than 1 possibility,
and the appropriate AR term is chosen in conjunction with
the MA value. Second, the integrated term deals with the
stationarity aspect of the data, which is evaluated using the
Dickey-Fuller test.10,11 If there is a lack of stationarity, then
differencing is undertaken in an attempt to achieve statio-
narity.11 In the present study, when differencing did not ach-
ieve stationarity, a log binomial model was used. Log binomial
models analyze dichotomous outcomes, similar to logistic
regression, but report outcomes as risk rather than odds. With
the exception of the pediatrics and ON groups, all populations
achieved stationarity, although the elderly group required dif-
ferencing to achieve stationarity. Third, the MA term is evalu-
ated with an autocorrelation function and, similar to the AR
term, can have multiple possible values. Although the AR term
and MA term have multiple possible values, and therefore
numerous combinations of values, individual models of each
possible value are created and evaluated for best fit. The best
fitting models were chosen using a combination of the lowest
Akaike information criterion, Bayesian information criterion,
and root mean square error from each AR–MA combination. If a
clear delineation between 2 models could not be made based
on these criteria, then a visual inspection of the graph was used
(ie, if one of the competing models displayed an incongruous
narrowing prediction interval [PI]).
Once the model was selected, prevalence was forecasted.
Forecasting was done using a simulation projected to 2030.
Prevalence (per 100,000 persons) was forecasted to 2030, and





AT95% PIs were calculated from the standard deviation derived
during forecasting. PIs are probability limits for a forecast that
denote a prediction’s accuracy.10 Average annual percentage
change, with confidence interval (CI), was calculated for each
model based on the forecasted prevalence and associated PI
using a separate log binomial model on forecasted values only.
The total number of people diagnosed with IBD in 2030 and
age- and sex-stratified and disease-specific subsets for CD and
UC were calculated using forecasted prevalence multiplied by
forecasted population values from Statistics Canada.12 Analyses
were performed using STATA 14.13 The interactive web-based
map was created with ArcGIS Pro 2.3.0 and ArcGIS Online
(Environmental Systems Research Institute, Redlands, CA).
Sensitivity Analyses
Four sensitivity analyses were conducted. The first analysis
used log binomial models instead of ARIMA. The second
sensitivity analysis used ARIMA to contrast the total number of
people with IBD (ie, total count) with the calculated prevalence
(ie, per 100,000).7 These first 2 sensitivity analyses were done
to assess the validity of the results from the primary analysis.
The third sensitivity analysis evaluated provinces with vali-
dated coding algorithms for their study populations (AB, MB,
and ON); this was done to assess the extent of misclassification
bias from provinces with non-validated algorithms. The prev-
alence for Canada was evaluated using a longer period (2002–
2013) to assess the effect that a longer period has on these
estimates. In this last sensitivity analysis, NS and QC were
removed because data were not available for those provinces
for the full 12-year period.
Results
Provincial Analyses
The age- and sex-standardized prevalence of IBD across
Canada in 2008 ranged from 445 per 100,000 in QC to 870
per 100,000 in NS (Table 1). The forecasted prevalence of
IBD in 2018 for each province ranged from 652 per 100,000
(95% PI 619–686) in MB to 1224 per 100,000 (95% PI
1156–1292) in NS (Table 1 and Figure 1). In 2030, the
forecasted prevalence of IBD ranged from 819 per 100,000
(95% PI 723–917) in MB to 1657 per 100,000 (95% PI
1531–1783) in NS (Table 1 and Figure 1). Figure 1 presents
the annual actual prevalence of IBD for each province fol-
lowed by the forecasted prevalence, with associated 95% PI.
The forecasted prevalence average annual percentage
changes ranged from 2.00% (95% CI 1.29–2.61) in MB to
3.89% (95% CI 3.85–3.94) in ON (Table 1 and Figure 1).
National Analyses
In 2008, the calculated prevalence of IBD in Canada was
510 per 100,000, with CD at 263 per 100,000 and UC at 226
per 100,000 (Table 1 and Figure 2), which equates to
169,564 individuals with IBD. In 2018, the prevalence in
Canada was estimated at 725 per 100,000 (95% PI 716–
735) for IBD, 368 per 100,000 (95% PI 363–373) for CD,
and 322 per 100,000 (95% PI 318–326) for UC; this equates
to 267,983 (95% PI 264,579–271,387) individuals with IBD,
135,899 (95% PI 134,065–137,734) with CD, and 118,918
(95% PI 117,424–120,412) with UC (Table 1 and Figure 2).The average annual percentage change of IBD preva-
lence in Canada was estimated at 2.86% (95% CI 2.80–2.92;
Table 1). The forecasted IBD prevalence in 2030 was 981
per 100,000 (95% PI 963–999), including 493 per 100,000
(95% PI 483–502) with CD and 436 per 100,000 (95% PI
428–444) with UC (Table 1 and Figure 2). The total number
of individuals with IBD in 2030 was forecasted at 402,853
(95% PI 395,466–410,240) with IBD, 202,216 (95% PI
198,299–206,133) with CD, and 178,909 (95% PI 175,635–
182,184) with UC (Table 1).
When stratifying the population by sex, the male prev-
alence of IBD was 477 per 100,000 persons in 2008,
increasing to 682 per 100,000 persons (95% PI 671–692) in
2018 and 925 per 100,000 persons (95% PI 905–946) in
2030 (Table 1 and Figure 2). The female prevalence showed
similar trends, with a prevalence of 542 per 100,000 per-
sons in 2008, 768 per 100,000 persons (95% PI 758–779)
in 2018, and 1036 per 100,000 persons (95% PI 1017–
1055) in 2030. These 2030 prevalence estimates equate to
approximately 188,326 male persons (95% PI 184,110–
192,542) and 214,402 female persons (95% PI 210,487–
218,317) with IBD (Table 1 and Figure 2). When stratified
by age group, the 2008 prevalence of IBD was 62 per
100,000 in children, 622 per 100,000 in adults, and 646 per
100,000 in the elderly (Table 1 and Figure 3). In 2030, the
estimated prevalence of IBD was 159 per 100,000 (95% PI
133–185) in children, 1118 per 100,000 (95% PI 1069–
1168) in adults, and 1370 per 100,000 (95% PI 1312–1429)
in the elderly (Table 1 and Figure 3). These prevalence es-
timates equate to approximately 12,647 children (95% PI
10,592–14,702), 238,915 adults (95% PI 228,267–
249,563), and 160,736 elderly adults (95% PI 153,898–
167,574) living with IBD in 2030 (Table 1 and Figure 3). All
estimates for CD and UC by sex or age group are presented
in Table 1.
Sensitivity Analyses
The first sensitivity analysis using log binomial
regression yielded a forecasted IBD prevalence in 2018 at
828 per 100,000 (95% PI 816–839), with an increase
to 1459 per 100,000 (95% PI 1421–1497) in 2030
(Appendix 2).
The second sensitivity analysis performed on the total
count compared with the calculated prevalence (per
100,000) showed prevalence values that were marginally
lower than those found in the primary analysis; this resulted
in a forecasted 2030 prevalence of 856 per 100,000 (95% PI
835–876) for all IBD cases, 493 per 100,000 (95% PI 483–
502) for CD, and 380 per 100,000 (95% PI 372–388) for UC
(see Appendix 2 for further details).
The third sensitivity analysis, using only provinces with
validated algorithms, forecasted a prevalence of IBD at 909
per 100,000 (95% PI 842–976) in 2030 (Appendix 2); this
95% PI overlaps with the 95% PI in the primary analysis,
suggesting similar results from the primary and sensitivity
analyses (Table 1 and Appendix 2).
The fourth sensitivity analysis, removing NS and
QC from the model to allow for a longer period of anal-
ysis, resulted in values similar to those seen in the



























2008 2018 2030 2008 2018 2030 2008 2018 2030
AB 529 729 (686–771) 1048 (882–1214) 3.14 (2.12–3.96) 282 352 (333–372) 482 (403–562) 2.71 (1.61–3.59) 183 256 (240–273) 376 (312–441) 3.33 (2.22–4.21)
BC 515 682 (659–705) 912 (841–984) 2.54 (2.07–2.96) 228 295 (285–306) 390 (357–422) 2.41 (1.92–2.85) 259 348 (338–358) 466 (433–499) 2.55 (2.14–2.93)
MB 567 652 (619–686) 819 (723–917) 2.00 (1.29–2.61) 283 316 (299–333) 390 (340–439) 1.84 (1.07–2.49) 285 338 (321–356) 433 (384–483) 2.18 (1.51–2.75)
NS 870 1224 (1156–1292) 1657 (1531–1783) 2.86 (2.55–3.14) 412 554 (522–587) 728 (667–789) 2.55 (2.20–2.86) 350 503 (474–532) 692 (634–750) 3.03 (2.68–3.34)
ON 507 731 (728–735) 1156 (1144–1169) 3.89 (3.85–3.94) 243 335 (332–337) 500 (493–508) 3.40 (3.34–3.47) 247 363 (360–365) 591 (582–600) 4.16 (4.09–4.22)
QC 445 671 (653–690) 940 (905–975) 3.25 (3.12–3.36) 278 427 (415–439) 604 (581–627) 3.37 (3.24–3.49) 168 244 (232–256) 336 (314–357) 3.03 (2.83–3.21)
SK 555 636 (606–666) 893 (707–1080) 2.89 (1.29–4.13) 316 358 (343–373) 491 (399–583) 2.69 1.26–3.82) 239 279 (264–294) 403 (313–493) 3.13 (1.41–4.43)
All 510 725 (716–735) 981 (963–999) 2.86 (2.80–2.92) 263 368 (363–373) 493 (483–502) 2.75 (2.69–2.81) 226 322 (318–326) 436 (428–444) 2.87 (2.81–2.93)
Sex stratification
Female 542 768 (758–779) 1036 (1017–1055) 2.83 (2.77–2.88) 296 409 (403–415) 542 (531–554) 2.65 (2.59–2.72) 224 321 (317–325) 437 (429–445) 2.92 (2.87–2.98)
Male 477 682 (671–692) 925 (905–946) 2.89 (2.82–2.97) 229 326 (321–331) 441 (432–450) 2.87 (2.80–2.94) 229 323 (319–327) 435 (426–443) 2.81 (2.75–2.88)
Age stratification
Pediatric (<18)a 62 96 (88–104) 159 (133–185) 4.32 (3.57–4.93) 40 58 (52–64) 91 (72–109) 3.76 (2.81–4.50) 19 29 (25–34) 51 (35–66) 4.59 (3.05–5.66)
Adult (18–59)b 622 849 (823–876) 1118 (1069–1168) 2.59 (2.43–2.74) 336 453 (430–476) 590 (547–633) 2.48 (2.24–2.70) 262 357 (351–364) 470 (457–483) 2.56 (2.47–2.65)
Elderly (60) 646 976 (950–1002) 1370 (1312–1429) 3.24 (3.06–3.40) 275 427 (416–438) 610 (586–633) 3.42 (3.27–3.56) 340 500 (486–513) 691 (660–721) 3.07 (2.89–3.24)
AAPC, average annual percentage change.
aYounger than 18 years for AB, BC, MB, ON, QC, and SK and <20 years for NS.









Figure 1. Actual and fore-
casted prevalence of IBD
in Canada by province.
Actual prevalence, stan-
dardized for age and sex,
is denoted by the solid
line. Forecasted preva-
lence—analyzed with an
ARIMA model and then
forecasted until 2030—is
indicated by a dashed
line with the PI high-
lighted in gray. For an









ATprimary analysis, with an IBD prevalence estimate of 700
per 100,000 (95% PI 680–719) in 2018 and 931 per
100,000 (95% PI 882–980) in 2030 (Appendix 2).
An interactive web-based map describing the prevalence
of IBD across Canada from 2002 to 2030 is available
at this link: https://people.ucalgary.ca/wggkaplan/
IBDCPREV.html.Discussion
We conducted a nationwide study using historical
population-based data from 7 provinces to estimate the
current, and forecast the future, prevalence of IBD. In 2008,
approximately 0.5% of the Canadian population had IBD; by
2018, prevalence was estimated at 0.7%; and, by 2030, itFigure 2. Actual and fore-
casted prevalence of IBD
in male and female pa-
tients and total patients in
Canada. Actual preva-
lence, standardized for
age and sex, is denoted by
the solid line and preva-
lence is calculated through
summation of total
affected individuals and
total population from each
province. Forecasted
prevalence—analyzed with
an ARIMA model and then
forecasted until 2030—is
indicated by a dashed line
with the PI highlighted in
gray.
Figure 3. (A) Actual and forecasted prevalence of pediatric IBD, CD, and UC in Canada. Actual prevalence, standardized for
sex and age, is denoted by the solid line. Forecasted prevalence—analyzed with a log binomial model and then forecasted
until 2030—is indicated by a dashed line with the PI highlighted in gray. (B) Actual and forecasted prevalence of adult IBD, CD,
and UC in Canada. Actual prevalence, standardized for age and sex, is denoted by the solid line. Forecasted preva-
lence—analyzed with an ARIMA model and then forecasted until 2030—is indicated by a dashed line with the PI highlighted in
gray. (C) Actual and forecasted prevalence of elderly IBD, CD, and UC in Canada. Actual prevalence, standardized for age and
sex, is denoted by the solid line. Forecasted prevalence—analyzed with an ARIMA model in which the data underwent dif-
ferencing and then forecasted until 2030—is indicated by a dashed line with the PI highlighted in gray.
1350 Coward et al Gastroenterology Vol. 156, No. 5
CLINICAL
ATwas forecasted to increase to 1.0%. We estimate that
approximately 270,000 Canadians are currently living with
IBD and that, by 2030, the Canadian health care systems
might be caring for more than 402,000 patients with IBD.
Prevalence is increasing in all age groups, but particularly
among the elderly because of newly diagnosed seniors and
the advancing age of patients with previously diagnosed
IBD. Ambulatory clinics in 2030 will be distinctly different
from current clinics as health care providers contend with
caring for considerably more patients with IBD—including
younger newly diagnosed patients and older patients with
longer disease duration and comorbidities of advancing age.
The prevalence of IBD is forecasted to increase steadily
by 2.86% per year in Canada. As a lifelong disease without a
cure, the compounding prevalence of IBD is due to the
disparity between incidence and mortality. Because changes
in incidence are inherently captured within our models of
changing prevalence (a combination of new cases, current
cases, and cases removed from the population), we did not
separately analyze incidence. As long as the incidence ex-
ceeds the mortality, our clinics will continue to add newlydiagnosed patients on the foundation of our previously
diagnosed patients every year. However, future studies ac-
counting for life expectancy are necessary to establish the
threshold that incidence needs to decrease for prevalence to
stabilize. Nonetheless, these data should serve as a clarion
call to health care systems to prepare their infrastructure,
personnel, and resources to manage the rising burden of IBD.
With 95% of the Canadian population represented by
our study, the findings are generalizable to other western-
ized nations with similar rates and demographics of IBD. For
example, similar to Canada, the prevalence of IBD is
increasing steadily in the United States.3,14 A series of
studies documenting this trend in Olmsted County, Minne-
sota was published using data ranging from 1940 to
2010.15,16 In 2001, the prevalence of IBD in Olmsted County
was 388 per 100,000 and increased to 533 per 100,000 in
2010; this equates to an estimated 1.64 million individuals
living with IBD as of 2010 in the United States.15–17 If the
prevalence increases to the same level as in Canada—0.98%
in 2030—more than 3.48 million individuals could have IBD
in the United States, more than double the 2010 estimate.18





ATMoreover, similar trends of rising prevalence have been
observed in Europe and Australia.3 Thus, a strategy to
address the compounding prevalence of IBD in the Western
world is necessary. Although our data are less applicable
outside the Western world, where prevalence of IBD re-
mains low, the rapidly increasing incidence of IBD in newly
industrialized countries in Asia and Latin America suggests
that these countries might begin to experience compound-
ing prevalence analogous to the Western world in a gener-
ation from now.3,5
Although the exact future prevalence of IBD is unknown,
it is apparent that the prevalence will continue to increa-
se—so, how do health care systems adapt? By bringing
awareness of this impending burden to the public and
physicians alike, we can increase community engagement
and bring this disease to the forefront of policy makers’
agendas. This awareness could lead to an influx of funding
for laboratory and epidemiologic research, which in turn
will aid in preventing disease by furthering the knowledge
base and thus working to lower the incidence of disease. If
we cannot prevent new cases of IBD, then the forecasted
increases in prevalence will lead to increased overall costs
to health care systems, especially with medications, some of
which can exceed tens of thousands of dollars per year per
individual. Identifying the current drivers of cost and pro-
jecting the costs into the future are paramount to being able
to define the future burden of disease, evaluate the future
impact on health care systems, and ensure access and
affordability. Further, developing alternative care pathways
(eg, nurse practitioners) will help to ensure that those with
IBD still receive the necessary care without health care
systems being overwhelmed.
This study forecasts the future prevalence of IBD, but it
is not without limitations. Heterogeneity in prevalence was
observed between provinces. NS had the highest prevalence
of IBD. Because NS is the only Atlantic province in
the dataset, we could not assess whether the high preva-
lence value was representative of the east coast of Canada
or unique to NS. Heterogeneity between provinces can be
explained by inherent differences between populations,
such as demography, genetic penetrance, and environmental
exposures associated with IBD (eg, diet).5 The models do
not directly account for future variations in environmental
risk factors (eg, breastfeeding or smoking) that can influ-
ence incidence, because these data were not available at the
individual level for this cohort.19 Further, because preva-
lence was calculated using administrative health care data-
bases, possible misclassification errors in the diagnosis of
IBD can occur.19–22 To overcome this, AB, MB, and ON use
validated algorithms, which ensure accuracy of the data
based on sensitivity, specificity, and predictive values of
diagnostic codes. The other provinces have applied these
algorithms without cross-referencing accuracy with chart
reviews. However, our sensitivity analysis—evaluating only
the provinces with validated algorithms—produced preva-
lence estimates consistent with our main analyses.19,21 Also,
our national estimates of IBD include all patients with IBD;
however, 5.6% of patients have unclassified IBD. These
patients have IBD, but the algorithm used to distinguish CDfrom UC cannot differentiate the specific subtype. In
consequence, the CD and UC stratified analyses do not ac-
count for these individuals. In addition, provinces report
different timeframes based on available data: MB contains
the longest period (1990–2013) and QC contains the
shortest (2001–2008). Thus, our primary national model
was restricted to 2002–2008 that included prevalence data
from all 7 provinces. However, a sensitivity analysis of 5
provinces with prevalence data spanning 2002–2013 yiel-
ded similar estimates on forecasted prevalence (931 per
100,000 in 2030) compared with our primary national
model (981 per 100,000). Further, there is an inherent
uncertainty associated with forecast modeling because the
methodology forecasts future values that are yet unknown
based on an assumption that historical trends (eg, inci-
dence rates) will be similar in the future. To address this,
PIs are created that acknowledge this uncertainty and give
a range of possible values for the true prevalence. The use
of the best fitting models also mitigates this limitation by
ensuring that forecasting models are true to the current
data. Moreover, sensitivity analyses using alternate fore-
casting approaches (ie, log binomial modeling) yield
similar estimates.
Forecasting the number of people with IBD alone is
insufficient in defining the overall burden of IBD. We
anticipate that the future landscape of IBD will evolve:
increased use of biologics and new therapies in the pipeline,
decreasing rates of hospitalization and surgery, and
unpredictability of a landmark discovery, including a po-
tential cure.23,24 Future studies are necessary to integrate
rising prevalence with other clinical factors that influence
the burden of IBD to the health care system.
Overall, the future prevalence of IBD will lead to an
increased stress on health care systems. We are at a time
when new policies and innovations in the delivery of IBD
care can help ensure that the nearly 4millionpatientswith IBD
in North America (by 2030) will continue to receive the
necessary care in the future. If health care systems fail to adjust
for the impending burden of IBD, then they will be over-
whelmed, and patients might not receive the care they need.
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Mid-year (July 1) Calendar year (January
1–December 31)
Fiscal year (April 1–March 31) Mid-year (July 1) Fiscal year (April
1–March 31)
Diseases classified CD, UC, IBD-U, IBD CD, UC, IBD-U, IBD CD, UC, IBD CD, UC, IBD-U, IBD CD, UC, IBD-U, IBD CD, UC, IBD CD, UC, IBD
Identification algorithm
validation reference
Rezaie et al, 20121 Rezaie et al, 20121 Bernstein et al, 19992 N/A Adults: Benchimol et al, 20143;
pediatrics: Benchimol et al,
20094
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or 4 physician claims
or 2 medical contacts
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claims or 2 medical
contacts in 2 y)
Adults 18–64 y: 5 physician
contacts or
hospitalizations within 4 y;
adults 65 y: pharmacy
claim for IBD medication þ
5 physician contacts or
hospitalizations within 4 y;
children<18 y: if scoped: 4
OHIP or 2 CIHI-DAD within
3 y; if not scoped: 7 OHIP
or 2 CIHI-DAD within 3 y
AB (2 hospitalizations or 4
physician claims or 2
medical contacts in 2 y)
MB (5 physician contacts
or CIHI-DAD records
within 2 y of health
coverage, and 3
separate contacts with










N/A Pediatrics (<18 y): sensitivity
86.9%–91.1%, positive
predictive value 57.7%–
75.2%; adults (18–64 y):
sensitivity 76.8%–92.3%,
positive predictive value
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NACRS Manitoba Health Physicians
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Frolkis et al, 201411;
Kuenzig et al,
201712
N/A Benchimol et al, 201713;
Melesse et al, 201514
and 201715; Shaw et al,
2013,16 2014,17 and
201518
Leddin et al, 201419 Benchimol et al, 2014,20
2014,21 and 201522;
Bollegala et al, 201723;
Nguyen et al, 201524
Bitton et al, 201425 Pena-Sanchez et al, 201726
Cases of IBD in 2008
(real)a
18,269 22,937 6516 8104 64,963 35,005 5357
Cases of IBD in 2008
(standardized)b
19,039 22,420 6795 8143 65,278 34,567 5643
Population size in 2008 3,595,755 4,499,139 1,197,774 935,865 12,882,625 7,761,504 1,017,346
CIHI-DAD, Canadian Institute for Health Information–Discharge Abstract Database; ED, emergency department; IBD-U, inflammatory bowel disease–unclassified; MSB,
Medical Services Billing; MSI, Medical Services Incorporated; N/A, not applicable; NACRS, National Ambulatory Care Reporting System; OHIP, Ontario Health Insurance Plan;
PHRS, Person Health Registration System; RAMQ, Régie de l’assurance maladie du Québec; RPDB, Registered Persons Database.
aNumbers presented might vary from actual numbers in the original administrative data: suppressed cells occurred in data provided by provinces, which altered the final
values contained in the analysis compared with the original.








Appendix 2.Sensitivity Analyses of Forecasted Prevalence and AAPC
IBD CD UC
Forecasted prevalence








per 100,000 (95% PI)
Forecasted AAPC,
% (95% CI)2018 2030 2018 2030 2018 2030
All log binomial regression 828 (816–839) 1459 (1421–1497) 4.85 (4.74–4.96) 414 (406–422) 706 (680–732) 4.55 (4.40–4.70) 368 (360–375) 652 (626–678) 4.89 (4.72–5.05)
Using population values 684 (673–694) 856 (835–876) 2.23 (2.13–2.32) 368 (363–373) 493 (483–502) 2.75 (2.69–2.81) 303 (300–307) 380 (372–388) 2.23 (2.15–2.32)
Canada (validated algorithms) 681 (661–701) 909 (842–976) 2.52 (2.09–2.91) 319 (307–330) 412 (376–449) 2.25 (1.71–2.74) 309 (289–328) 413 (357–469) 2.55 (1.74–3.23)
Canada (without NS or
QC: 2002–2013)
700 (680–719) 931 (882–980) 2.52 (2.25–2.77) 327 (317–336) 425 (400–450) 2.33 (2.02–2.61) 328 (316–340) 438 (409–468) 2.57 (2.24–2.88)
AAPC, average annual percentage change.
April2019
Canadian
Prevalence
of
IBD
1353.e4
